The AAN has published a new guideline on the use of the drug natalizumab for the treatment of multiple sclerosis (MS).
Strong evidence suggests that natalizumab reduces disease activity and severity in people with relapsing MS by both clinical and MRI measures.
Additionally, strong evidence suggests an increased risk of developing PML in patients receiving combination therapy with interferon (IFN) and natalizumab. Because of the possibility that natalizumab therapy may be responsible for the increased risk of progressive multifocal leukoencephalopathy (PML), it is recommended that natalizumab be reserved for use in selected patients with relapsing-remitting disease who have failed other therapies either through continued disease activity or medication intolerance, or who have a particularly aggressive initial disease course.
The guideline found insufficient evidence to compare the efficacy of natalizumab to other available disease-modifying therapies.